IBM Watson Health and OrbitalRX to Launch Integrated Solution to Assist Hospital Pharmacy Providers in Managing Drug Shortages

Joint offering pairs pharmacy supply chain management capabilities with evidence-based drug content, designed to help hospital pharmacy teams manage drug shortages CAMBRIDGE, Mass. and WINSTON-SALEM, N.C., Sept. 1, 2020 /PRNewswire/ — IBM (NYSE: IBM) Watson Health and OrbitalRX® today announced a strategic collaboration that aims to help address the emerging drug shortage crisis. The companies are combining OrbitalRX’s Drug Shortage Management Platform and IBM® Micromedex® into one unified solution called “OrbitalRX and Micromedex,” designed to create a single source for healthcare providers and pharmacy teams to access evidence-based treatment information alongside a hospital’s current drug inventory status and drug sourcing options. This one solution aims to quickly analyze the supply chain and identify clinical alternatives for drugs that are in short supply. The global drug shortage crisis has accelerated at an alarming rate during the COVID-19 crisis. According to the American Society of Health-Systems Pharmacists (ASHP), close to 200 drugs are currently on the drug shortage list in the U.S. alone. Management of these shortages is further complicated by the fact that shortages vary by drug and location, as noted by the American Medical Association (AMA). The new solution, OrbitalRX and Micromedex, will be designed to evaluate important drug information, clinical evidence, and comparative efficacy, alongside the hospital’s drug inventory, purchase history, and utilization data, enabling hospital providers, pharmacists and pharmacy technicians to proactively manage drug shortages. “As hospitals around the world experience shortages of life-saving therapies, there is an immediate, critical need for evidence-based information around clinical alternatives,” said Todd Nolen, General Manager, IBM Micromedex Solutions, IBM Watson Health. “We are addressing this critical need by combining our Micromedex content with powerful insights from the OrbitalRX platform. Our goal is to deliver a trusted platform to help pharmacists and other healthcare providers streamline workflow and rapidly respond to drug shortages with appropriate, safe and effective alternative therapies.” IBM Micromedex is one of the largest online reference databases for medication information. It is used by more than 4,500 hospitals and health systems worldwide to help support decision-making in medication therapy management, disease and condition management, toxicology, alternative medicine and patient education. OrbitalRX is the only platform designed by hospital pharmacists, for hospital pharmacists, to unify supply chain and clinical utilization to manage drug shortages and deliver the power of real-time situational awareness in hospital pharmacy workflows. “Patient safety can be compromised by supply chain interruptions, limited drug access due to high medication costs, and unforeseen events like COVID-19. OrbitalRX and Micromedex aim to help health system pharmacy departments mitigate these workflow challenges by identifying drug alternatives from a clinical and supplier perspective,” said OrbitalRX co-founder and CEO, Adam Orsborn, PharmD, MS. “Rooted in cloud-based technology and evidence-based insights, this new, unified solution is designed to deliver workflow efficiencies that will empower pharmacists and providers to prioritize therapeutic needs.”  “Hospital resources are scarcer than ever, especially with drug shortages and supply chain inefficiencies conspiring daily to upend the rigorous efforts of health systems to improve care quality while reducing cost,” said OrbitalRX co-founder and Chief Product Officer, Nate Peaty, PharmD, MS. “With these challenges in mind, OrbitalRX and Micromedex plan to provide health systems with a highly intelligent and automated solution designed to help them with one of the most frustrating issues they face today.”   OrbitalRX and Micromedex is anticipated to be available in Q4 2020. Please visit www.ibm.com/products/orbitalrx-micromedex.com to learn more about the solution, schedule a live demo, or to register for a webinar on September 24 to learn more. About IBM Watson HealthIBM Watson Health is a data, analytics, and technology partner for the health industry. Supported by the innovation of IBM and intelligence of Watson, we are committed to helping build smarter health ecosystems. Through the combination of our deep industry expertise in health, data and analytics, actionable insights, and reputation for security and trust, Watson Health is working together with its clients and partners to help them achieve simpler processes, better care insights, faster breakthroughs, and improved experiences for people around the world. Learn more at www.ibm.com/watson-health. For more information about IBM visit, www.ibm.com. Statements regarding IBM’s future direction and intent are subject to change or withdrawal without notice and represent goals and objectives only.  About OrbitalRX Co-founded by health-system pharmacy leaders, OrbitalRX offers a one-of-a-kind drug shortage management platform which helps to identify risk factors using internal and external data for when a medication shortage could cause harm in your health-system. We offer everything you need to anticipate, evaluate, take action, follow-up, and report in a single, powerful platform designed to improve your overall shortage management strategy. To learn more about how we’re changing the way hospital pharmacies monitor their supply and manage shortages in the supply chain, visit www.orbitalrx.com.   IBM Media ContactMatthew Henson917-930-7147matthew.henson@ibm.com OrbitalRX Media Contact  Emily Nichols emily@orbitalrx.com SOURCE IBM Watson Health

Joint offering pairs pharmacy supply chain management capabilities with evidence-based drug content, designed to help hospital pharmacy teams manage drug shortages

CAMBRIDGE, Mass. and WINSTON-SALEM, N.C., Sept. 1, 2020 /PRNewswire/ — IBM (NYSE: IBM) Watson Health and OrbitalRX® today announced a strategic collaboration that aims to help address the emerging drug shortage crisis. The companies are combining OrbitalRX’s Drug Shortage Management Platform and IBM® Micromedex® into one unified solution called “OrbitalRX and Micromedex,” designed to create a single source for healthcare providers and pharmacy teams to access evidence-based treatment information alongside a hospital’s current drug inventory status and drug sourcing options. This one solution aims to quickly analyze the supply chain and identify clinical alternatives for drugs that are in short supply.

IBM Corporation logo. (PRNewsfoto/IBM)

The global drug shortage crisis has accelerated at an alarming rate during the COVID-19 crisis. According to the American Society of Health-Systems Pharmacists (ASHP), close to 200 drugs are currently on the drug shortage list in the U.S. alone. Management of these shortages is further complicated by the fact that shortages vary by drug and location, as noted by the American Medical Association (AMA).

The new solution, OrbitalRX and Micromedex, will be designed to evaluate important drug information, clinical evidence, and comparative efficacy, alongside the hospital’s drug inventory, purchase history, and utilization data, enabling hospital providers, pharmacists and pharmacy technicians to proactively manage drug shortages.

“As hospitals around the world experience shortages of life-saving therapies, there is an immediate, critical need for evidence-based information around clinical alternatives,” said Todd Nolen, General Manager, IBM Micromedex Solutions, IBM Watson Health. “We are addressing this critical need by combining our Micromedex content with powerful insights from the OrbitalRX platform. Our goal is to deliver a trusted platform to help pharmacists and other healthcare providers streamline workflow and rapidly respond to drug shortages with appropriate, safe and effective alternative therapies.”

IBM Micromedex is one of the largest online reference databases for medication information. It is used by more than 4,500 hospitals and health systems worldwide to help support decision-making in medication therapy management, disease and condition management, toxicology, alternative medicine and patient education. OrbitalRX is the only platform designed by hospital pharmacists, for hospital pharmacists, to unify supply chain and clinical utilization to manage drug shortages and deliver the power of real-time situational awareness in hospital pharmacy workflows.

“Patient safety can be compromised by supply chain interruptions, limited drug access due to high medication costs, and unforeseen events like COVID-19. OrbitalRX and Micromedex aim to help health system pharmacy departments mitigate these workflow challenges by identifying drug alternatives from a clinical and supplier perspective,” said OrbitalRX co-founder and CEO, Adam Orsborn, PharmD, MS. “Rooted in cloud-based technology and evidence-based insights, this new, unified solution is designed to deliver workflow efficiencies that will empower pharmacists and providers to prioritize therapeutic needs.” 

“Hospital resources are scarcer than ever, especially with drug shortages and supply chain inefficiencies conspiring daily to upend the rigorous efforts of health systems to improve care quality while reducing cost,” said OrbitalRX co-founder and Chief Product Officer, Nate Peaty, PharmD, MS. “With these challenges in mind, OrbitalRX and Micromedex plan to provide health systems with a highly intelligent and automated solution designed to help them with one of the most frustrating issues they face today.”  

OrbitalRX and Micromedex is anticipated to be available in Q4 2020. Please visit www.ibm.com/products/orbitalrx-micromedex.com to learn more about the solution, schedule a live demo, or to register for a webinar on September 24 to learn more.

About IBM Watson Health
IBM Watson Health is a data, analytics, and technology partner for the health industry. Supported by the innovation of IBM and intelligence of Watson, we are committed to helping build smarter health ecosystems. Through the combination of our deep industry expertise in health, data and analytics, actionable insights, and reputation for security and trust, Watson Health is working together with its clients and partners to help them achieve simpler processes, better care insights, faster breakthroughs, and improved experiences for people around the world. Learn more at www.ibm.com/watson-health.

For more information about IBM visit, www.ibm.com. Statements regarding IBM’s future direction and intent are subject to change or withdrawal without notice and represent goals and objectives only. 

About OrbitalRX
Co-founded by health-system pharmacy leaders, OrbitalRX offers a one-of-a-kind drug shortage management platform which helps to identify risk factors using internal and external data for when a medication shortage could cause harm in your health-system. We offer everything you need to anticipate, evaluate, take action, follow-up, and report in a single, powerful platform designed to improve your overall shortage management strategy. To learn more about how we’re changing the way hospital pharmacies monitor their supply and manage shortages in the supply chain, visit www.orbitalrx.com.  

IBM Media Contact
Matthew Henson
917-930-7147
matthew.henson@ibm.com

OrbitalRX Media Contact 
Emily Nichols 
emily@orbitalrx.com

SOURCE IBM Watson Health

This post was originally published on this site



For enquiries, product placements, sponsorships, and collaborations, connect with us at hello@globalcloudplatforms.com. We'd love to hear from you!


Our humans need coffee too! Your support is highly appreciated, thank you!

Total
0
Shares
Previous Article

Now Go Build - Season 2

Next Article

IBM Study: Consumers' COVID-19 outlook, optimism and preferences vary greatly across generations and geographies

Related Posts
Read More

IBM Watson Demonstrates New Natural Language Processing Advancement in Premiere of “That's Debatable”

New Key Point Analysis technology from IBM Research used to analyze 3,500+ viewer submissions and provide insight into the global public opinion on the motion, "It's time to redistribute the wealth"IBM plans to commercialize Key Point Analysis inside Watson NLP products including Watson Discovery ARMONK, N.Y., Oct. 12, 2020 /PRNewswire/ -- In the debut episode of "That's Debatable" on Bloomberg Television, IBM Watson used a new advancement in natural language processing (NLP) from IBM Research to provide insight into the global public opinion on the motion: "It's Time to Redistribute the Wealth." More than 3,500 submissions were collected online from around the world on the topic, analyzed and distilled into key points that were used in the debate. Experience the interactive Multichannel News Release here:  https://www.multivu.com/players/English/8668653-ibm-watson-thats-debatable-premiere/ "That's Debatable" – a new, limited series presented by Bloomberg Media and Intelligence Squared U.S. and sponsored exclusively by IBM (NYSE:IBM) – features industry leaders, economists, policy makers and public intellectuals debating some of today's most pressing issues. In its premiere on October 9, moderator and host John Donvan convened a vibrant debate with former U.S. Labor Secretary Robert Reich and former Greece Finance Minister Yanis Varoufakis arguing for the motion, against former U.S. Treasury Secretary Lawrence Summers and Manhattan Institute Senior Fellow Allison Schrager. To determine the winner of the debate, the virtual debate audience was polled on the motion prior to the start - 57 percent of the virtual audience was for, 20 percent against and 23 percent undecided. Following the debate, the audience voted again with 59 percent for and 37 percent against, declaring Schrager and Summers the winners with an increase of 17 percentage points.   The full episode can be viewed on Bloomberg.com/thats-debatable or via streaming services. To learn more about the arguments the debaters made, please visit Intelligence Squared US. Bringing More Global Voices To The Debate To bring even more global voices and ideas to the debate, "That's Debatable" used Key Point Analysis, a novel advancement in NLP from IBM Research, to determine the main points that mattered most to the public from more than 3,500 submissions online prior to the debate. Of the 3,500 submissions, there were 1,600 usable arguments and 20 key points identified. This analysis of global public submissions and arguments prompted further discussion and exchange of ideas amongst the debaters. Using Key Point Analysis, the technology identified: 56 percent of arguments analyzed were for redistributing wealth, with approximately 20 percent of analyzed submissions arguing that there is currently too much wealth inequality in the world. One argument was that income inequality has increased dramatically over the past few decades, causing excessive suffering to large populations, and that if wealth is not redistributed, far greater will suffer. The remaining 44 percent of analyzed arguments were against the motion, with 15 percent of those arguing that redistributing wealth would discourage some people from working hard. One example argument in support of this is that redistributing the wealth discourages individual initiative, entrepreneurship, and accountability for choices. How It Works Key Point Analysis is the next generation of NLP-based extractive summarization, evolved from extractive summarization capabilities first used with IBM Project Debater. To generate the key points, the system utilizes four steps: Classify Arguments: Every submission is analyzed using a deep neural network to determine if the content is for or against the position statement, and submissions deemed irrelevant or neutral are removed. Identify Key Points: From 3,508 arguments submitted on the first motion, 1,600 were deemed usable. The technology evaluates the quality of each argument and identifies potential key points by grading and filtering high-quality arguments. It disregards potential key points that are too long, too emotional in tone, are incoherent or include redundancies. From 1,600 usable arguments, 20 key points were identified. Match Arguments to Key Points: It identifies how many arguments support each of the potential key points. It then selects a small set of key points that are diverse and cover the majority of arguments submitted - giving a percentage of the prevalence of each. Generates the narrative: The technology selects the key points cited most often in the submissions and a small subset of the strongest arguments that support each key point are used to create salient narratives arguing the pro and con side of the debate. Beyond the Debate: Key Point Analysis Advancing the Language of Business Language can present a unique challenge for the business world – each company and industry has its own vernacular that evolves in response to new innovations, changing consumer expectations and world events. Additionally, the language of business is documented in many forms, from simple text to more complicated formats like charts, tables, PDFs, and images. NLP is the branch of AI that helps businesses interpret the trends and insights that may be hidden within this type of enterprise data. Key Point Analysis is the latest advancement from IBM designed to empower businesses to deploy and scale AI that provides greater accuracy and efficiency, including less data consumption and human oversight. IBM plans to  commercialize Key Point Analysis inside Watson NLP products including Watson Discovery. Using Key Point Analysis, businesses can gain a clearer view of relevant points and considerations to help make data-driven decisions on important operational questions such as pricing adjustments, product evolution, new marketing campaigns and inventory optimization. The use of Key Point Analysis in "That's Debatable" builds on a series of actions that demonstrate how IBM is advancing Watson's ability to understand the language of business to help companies generate new insights - from commercializing cutting-edge capabilities from Project Debater, to transforming the fan experience at the US Open and helping states get critical voting information to citizens. To try key point analysis, explore the results from the premiere episode, and join the debate for the next episode on "A U.S.-China Space Race Is Good for Humanity," visit ibm.com/debatable. Contact:Sarah MurphyIBM Media Relationssrmurphy@us.ibm.com Statements regarding IBM's future direction and intent are subject to change or withdrawal without notice, and represent goals and objectives only. SOURCE IBM